Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Addyi was the first drug approved to treat FSIAD. Addyi is designed for premenopausal people, and is available as a pill. A person takes this drug daily before bed, even if they do not intend to ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims & Hers Health. Looking at options history for Hims & Hers Health (NYSE:HIMS) we detected 16 trades. If we ...

This may look like: forgetting to take your pill within the same three-hour window each day incorrectly applying a new skin patch inserting a new vaginal ring a day later than expected missing ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, citing increased uncertainty following the recent FDA ruling on weight ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

The telehealth company acquired the personalised dermatology treatments player in 2021 Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ plan to combine all its dermatology services into one main ...